Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

Alshad S. Lalani,1 Susan E. Alters,1 Alvin Wong,1 Mark R. Albertella,2 Jeffrey L. Cleland,1 and William David Henner1

Abstract

Purpose: The antitumor activities and pharmacokinetics of the hypoxia-activated cytotoxin AQ4N and its metabolites were assessed in several preclinical models of pancreatic cancers.

Experimental Design: The cytotoxic effects of AQ4N prodrug and its bioreduced form, AQ4, were tested against multiple human tumor cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Nude mice bearing s.c. or orthotopically implanted human BxPC-3 or Panc-1 tumor cells were treated with AQ4N. Tumor growth inhibition, time to progression/endpoint, and liver metastasis were evaluated in treatment versus control groups. Plasma and tumor levels of AQ4N and its metabolites were quantitated by liquid chromatography-tandem mass spectrometry.

Results: In contrast to AQ4N, the bioreduced AQ4 metabolite displayed potent cytotoxicity in many human tumor lines, including those derived from human pancreatic adenocarcinomas. Single-agent administration of AQ4N significantly delayed tumor growth, progression, and survival in a manner comparable with gemcitabine in multiple pancreatic tumor models in vivo. Survival increases were accompanied by a reduction in incidence and spread of liver metastasis. Quantitation of AQ4N and its metabolites in tumor-bearing mice showed that the prodrug is rapidly cleared from the circulation by 24 h and neither of the bioreduced metabolites was detected in plasma. In contrast, AQ4N readily penetrated BxPC-3 tumors and the cytotoxic AQ4 metabolite rapidly accumulated in tumor tissues at high levels in a dose-dependent fashion.

Conclusion: AQ4N undergoes rapid and selective conversion into the potent antineoplastic metabolite AQ4 in tumors in vivo and provides proof of principle for the use of hypoxia-activated prodrugs in the treatment against pancreatic cancers.
four-electron reduction process, which seems to be mediated by cytochrome P450 (CYP) enzymes, including CYP3A4, CYP1A1, CYP1A2, and CYP2B6 (21, 23, 25–31). Many of these P450 isoforms are differentially expressed in a wide spectrum of human tumors and may contribute to the liberation of the cytotoxic AQ4 metabolite within hypoxic regions of tumors (32, 33). Once fully reduced, the highly stable AQ4 metabolite intercalates into DNA with high avidity, where it functions as a potent inhibitor of topoisomerase II, thereby arresting cellular proliferation (23, 24, 34, 35).

Tumor selectivity following AQ4N treatment in experimental human solid tumor models has not been well characterized. Given the extremely low oxygen tension found in pancreatic tumors and the selective bioactivation of AQ4N in hypoxic microenvironments, we hypothesized that AQ4N may have therapeutic utility in this aggressive neoplasm. Therefore, we evaluated the efficacy and tumor-targeting activity of AQ4N in vivo using multiple pancreatic xenograft models. In vitro, the bioreduced AQ4 metabolite showed potent antiproliferative activity in contrast to the low cytotoxic activity displayed by the AQ4N prodrug against a broad spectrum of human tumor cell lines. Here, we show that administration of AQ4N as a single agent has significant tumor growth-inhibitory and antimetastatic effects, in addition to prolonging the survival of nude mice bearing s.c. or orthotopically implanted human pancreatic tumors. Moreover, plasma and tumor pharmacokinetics following drug infusion reveal a dose-dependent accumulation of the fully bioreduced AQ4 cytotoxic metabolite in tumor tissues and a rapid clearance of the AQ4N prodrug from the systemic circulation. Thus, AQ4N may represent a novel tumor-targeting cytotoxic prodrug, which warrants further investigation in human clinical studies for the treatment of hypoxic tumors, such as pancreatic adenocarcinomas.

**Materials and Methods**

**IC_{50} determination on a panel of tumor lines.** Standard human tumor cell lines were obtained commercially and plated at appropriate cell densities (based on the *in vitro* doubling time of each cell line) in 96-well flat-bottomed microtiter plates and incubated at 37°C for 24 h in 0.1 ml of drug-free RPMI 1640 supplemented with 10% fetal bovine serum. Cells were subsequently exposed to AQ4, AQ4N, or a relevant chemotherapeutic agent (as a positive control, see Table 1) for 24 h under normoxic conditions in a 37°C humidified incubator. AQ4 was dissolved in 0.1% formic acid and then diluted in sterile water. AQ4N was dissolved in PBS, the pH adjusted to 6.8 using 5 N NaOH, and then diluted in RPMI 1640. Control cells were treated with the appropriate vehicle alone. Drug-containing medium was washed out and replaced by drug-free medium, and tumor cells were incubated for an additional 72 h. Cell viability was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and the IC_{50} values were determined from three independent experiments. IC_{50} was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay following 24-h drug exposure as described in the text.

**Table 1. Effects of AQ4, AQ4N, and standard agents on cell viability against a panel of human solid tumor lines *in vitro***

<table>
<thead>
<tr>
<th>Tumor line</th>
<th>Tumor type</th>
<th>AQ4 IC_{50} (μmol/L)</th>
<th>AQ4N IC_{50} (μmol/L)</th>
<th>Standard agent IC_{50} (μmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BxPC-3</td>
<td>Pancreatic</td>
<td>1.6</td>
<td>NA*</td>
<td>0.060 (gemcitabine)</td>
</tr>
<tr>
<td>Panc-1</td>
<td>Pancreatic</td>
<td>0.4</td>
<td>NA*</td>
<td>1.70 (gemcitabine)</td>
</tr>
<tr>
<td>Mia PaCa-2</td>
<td>Pancreatic</td>
<td>1.6</td>
<td>NA*</td>
<td>0.20 (gemcitabine)</td>
</tr>
<tr>
<td>HT-29</td>
<td>Colon</td>
<td>0.7</td>
<td>101.5</td>
<td>0.087 (SN38)</td>
</tr>
<tr>
<td>HCT-116</td>
<td>Colon</td>
<td>3.9</td>
<td>NA*</td>
<td>0.900 (SN38)</td>
</tr>
<tr>
<td>LoVo</td>
<td>Colon</td>
<td>0.2</td>
<td>49.9</td>
<td>0.024 (SN38)</td>
</tr>
<tr>
<td>LS174T</td>
<td>Colon</td>
<td>0.7</td>
<td>14.4</td>
<td>0.106 (SN38)</td>
</tr>
<tr>
<td>MCF-7</td>
<td>Breast</td>
<td>0.3</td>
<td>NA*</td>
<td>0.002 (paclitaxel)</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>Breast</td>
<td>2.7</td>
<td>NA*</td>
<td>NA (paclitaxel)</td>
</tr>
<tr>
<td>A-498</td>
<td>Renal cell</td>
<td>2.5</td>
<td>NA*</td>
<td>NA (paclitaxel)</td>
</tr>
<tr>
<td>Caki-1</td>
<td>Renal cell</td>
<td>1.8</td>
<td>NA*</td>
<td>NA (paclitaxel)</td>
</tr>
<tr>
<td>A2780</td>
<td>Ovarian</td>
<td>0.05</td>
<td>12.3</td>
<td>0.001 (paclitaxel)</td>
</tr>
<tr>
<td>OVCAR-3</td>
<td>Ovarian</td>
<td>2.7</td>
<td>NA*</td>
<td>0.015 (paclitaxel)</td>
</tr>
<tr>
<td>A549</td>
<td>NSCLC</td>
<td>0.1</td>
<td>85.4</td>
<td>0.010 (paclitaxel)</td>
</tr>
<tr>
<td>H460</td>
<td>NSCLC</td>
<td>1.4</td>
<td>103.0</td>
<td>0.006 (paclitaxel)</td>
</tr>
<tr>
<td>PC-3</td>
<td>Prostate</td>
<td>11.2</td>
<td>NA*</td>
<td>0.007 (paclitaxel)</td>
</tr>
<tr>
<td>LNCap-FGC</td>
<td>Prostate</td>
<td>0.8</td>
<td>43.0</td>
<td>0.002 (paclitaxel)</td>
</tr>
<tr>
<td>FaDu</td>
<td>Pharynx SCC</td>
<td>0.3</td>
<td>64.7</td>
<td>7.01 (paclitaxel)</td>
</tr>
<tr>
<td>KB</td>
<td>Oral carcinoma</td>
<td>0.6</td>
<td>13.4</td>
<td>2.00 (paclitaxel)</td>
</tr>
<tr>
<td>KB-3</td>
<td>Rad-resistant KB</td>
<td>3.3</td>
<td>NA*</td>
<td>19.10 (paclitaxel)</td>
</tr>
<tr>
<td>Hep3B2,1-7</td>
<td>Hepatocellular</td>
<td>0.8</td>
<td>NA*</td>
<td>1.40 (paclitaxel)</td>
</tr>
<tr>
<td>A375</td>
<td>Melanoma</td>
<td>3.3</td>
<td>NA*</td>
<td>0.006 (paclitaxel)</td>
</tr>
</tbody>
</table>

NOTE: The mean IC_{50} values were determined from three independent experiments. IC_{50} was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay following 24-h drug exposure as described in the text. Abbreviation: NSCLC, non – small cell lung cancer.

*N: Nonachievable under the physiologic/normoxic conditions tested.
schedule of gemcitabine were selected based on prior experience with gemcitabine in these in vivo models (36). Panc-1 tumors were measured with calipers twice weekly, and tumor volume was calculated using the following formula: tumor volume (mm³) = [(width)² × length] / 2. Animals were monitored for signs of toxicity and weighed daily for the first 5 days of the study and then twice weekly until the end study. As predefined in the protocol, each animal was actively euthanized when its tumor reached the predetermined end point size of 1,200 mm³ or at the conclusion of the study (day 60), whichever came first. The time to end point was calculated for each mouse as time to end point (days) = [log₁₀(end point volume mm³) – b] / m, where b is the intercept and m is the slope of the line obtained by linear regression of a log-transformed tumor growth data set. Treatment outcome was determined from tumor growth delay (TGD), which is defined as the increase in median time to end point in a treatment (T) group compared with the control (C) group (TGD = T – C) expressed in days or as a percentage of the median time to end point of the control group %TGD = [(T – C) / C] × 100.

Kaplan-Meier plots were constructed to show the percentage animals remaining in the study as a function of time following treatment. Statistical significance between the treated versus control groups was evaluated by log-rank analysis using Prism GraphPad software (GraphPad, San Diego, CA).

S.c. BxPC-3 xenograft model. Female nude mice (nu/nu) were implanted s.c. with fragments of human BxPC-3 pancreatic tumors. When the tumors reached approximately 60 to 80 mm³ in size, the animals were pair matched into treatment and control groups containing 10 mice per group. Treatment administration of AQ4N (i.v.) or gemcitabine (i.p.) was initiated the day animals were pair matched (day 1). Tumors were measured by calipers twice weekly and averaged to tumor volume by the following formula: tumor volume (mm³) = [(width)² × length] / 2. The experiment was terminated when the vehicle control group tumor size reached an average of 2,000 mm³ (27 days). On termination, the mice were weighed and sacrificed, tumors were excised, and the mean tumor volume per group was calculated. Tumor growth inhibition (TGI), defined as the change in mean tumor volume of the treated group/change in mean tumor volume of the control group × 100 (%TGI), was calculated for each group. Statistical comparisons were carried out using ANOVA followed by the Dunnett multiple comparisons test. All statistical analyses were done with Prism GraphPad software.

Orthotopic BxPC-3 xenograft model and histologic analysis. Female athymic NMRI mice were injected with 2.5 × 10⁶ human BxPC-3 pancreatic cells directly into the pancreas parenchyma. Treatment with AQ4N (i.v.) or gemcitabine (i.p.) was initiated the day the animals were pair matched (day 1). Tumors were measured by calipers twice weekly and averaged to tumor volume by the following formula: tumor volume (mm³) = [(width)² × length] / 2. The experiment was terminated when the vehicle control group tumor size reached an average of 2,000 mm³ (27 days). On termination, the mice were weighed and sacrificed, tumors were excised, and the mean tumor volume per group was calculated. Tumor growth inhibition (TGI), defined as the change in mean tumor volume of the treated group/change in mean tumor volume of the control group × 100 (%TGI), was calculated for each group. Statistical comparisons were carried out using ANOVA followed by the Dunnett multiple comparisons test. All statistical analyses were done with Prism GraphPad software.

Pharmacokinetic studies. Female C-17 severe combined immunodeficient mice (IFEA CREDO, L’Arbresles, France) were irradiated with a gamma source (1.8 Gy, Co-60, INRA, Dijon, France) 24 h before s.c. injection with 1 × 10⁶ BxPC-3 cells. Animals were dosed when the mean tumor volume reached 266 ± 88 mm³ (day 53). Mice were randomized into four groups of nine mice. The mice received a single i.v. bolus injection of AQ4N at 20, 60, 120, or 240 mg/kg via the caudal vein. Three mice per dose were sacrificed at 2, 8, and 24 h after treatment. Plasma and tumor samples were collected for further analysis using high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS; see below). Tumor samples were dried and stored at −80°C until analysis.

HPLC-MS/MS analysis of tumor and plasma samples. Quantitation of AQ4N and its metabolites, AQ4M and AQ4Q, from plasma and tumor samples was determined following liquid-liquid extraction in methanol containing 0.1% (v/v) acetic acid using a similar methodology that has been described previously (38). Following liquid extraction, plasma samples were added to known concentrations of the internal standard, mitoxantrone, and subjected to centrifugation at 15,000 rpm for 10 min at 4°C. The resulting supernatants were analyzed by HPLC-MS/MS as described below. Resected BxPC-3 tumor samples (~300 mg) were homogenized in cold water, added to mitoxantrone standard, and subjected to liquid-liquid extraction. Following the centrifugation of tissue homogenates, the supernatants were collected and concentrated to a final volume of 0.4 mL using a vacuum concentrator before HPLC-MS/MS analysis. Chromatographic analysis was done using a methodology adapted from Loadman et al. (38). Briefly, AQ4N, AQ4Q, and AQ4M were quantitated from plasma and BxPC-3 tumor samples using a Perkin-Elmer HPLC-MS/MS system (Perkin-Elmer, Wellesley, MA). Samples were separated by HPLC using a LiChroSpher RP select B 55 × 2 mm, 3 μm column protected with a 10μP HIRPB-10C guard cartridge, using a flow rate of 200 μL/min. The mass spectrometer worked in positive MS-MS mode, scanning in multiple reaction monitoring mode, using nitrogen as the collision gas. The ion transitions monitored for AQ4N, AQ4Q, AQ4M, and mitoxantrone were m/z 444→384, 412→72, 428→58, and 444>88 for AQ4N, AQ4Q, AQ4M, and mitoxantrone, respectively. The retention time of AQ4N, AQ4Q, AQ4M, and mitoxantrone was 1.7 min. Standard concentrations of AQ4N, AQ4M, and AQ4Q from stock solutions were prepared in 0.1% acetic acid. Calibration curves were prepared by spiking standard concentrations in blank (drug-free) plasma from 25 to 5,000 ng/mL or blank BxPC-3 tumor homogenate from 25 to 3,000 ng/mL.

Results

Growth inhibitory effects of AQ4N and AQ4Q in human tumor cells in vitro. Unlike the prodrug AQ4N, the bioreduced AQ4Q metabolite is a potent DNA intercalator and topoisomerase II inhibitor. We therefore compared the antiproliferative activity of AQ4Q and AQ4N against a panel of human solid tumor lines under normoxia in vitro (Table 1). For each cell line, parallel assays were also done using appropriate standard chemotherapeutic agents for relative comparison of the cytotoxic response. Table 1 summarizes the drug concentration required to block cell growth by 50% (IC₅₀) for each tumor line treated with AQ4N, AQ4Q, or standard agent.

AQ4Q was observed to have potent antiproliferative activity against all the solid tumor lines tested with an IC₅₀ in the low micromolar range. Interestingly, AQ4Q showed similar activity ranges in comparison with gemcitabine (0.4-1.6 μmol/L for AQ4Q; 0.02-1.7 μmol/L for gemcitabine) against the three pancreatic carcinoma tumor lines tested. Whereas gemcitabine seemed to have a greater inhibitory effect on the BxPC-3 and Mia PaCa-2 pancreatic lines, AQ4Q was shown to have more potent cytotoxic effects against Panc-1 cells. In the four human
colon tumor lines tested, the activity of AQ4 was an order of magnitude lower than SN38, the activated metabolite of irinotecan and a commonly used antineoplastic agent against colorectal cancer. AQ4 showed greater effects on cell viability than paclitaxel in all three head and neck lines as well as the hepatocellular carcinoma tumor lines (0.3-3.3 μmol/L for AQ4; 2.0-19.1 μmol/L for paclitaxel). In general, AQ4 was less potent than paclitaxel against the breast, ovarian, non–small cell lung, prostate, and melanoma cell lines.

In contrast to the broad-spectrum potent activity of AQ4, AQ4N was shown to have low or unmeasurable antiproliferative activity in the majority of human tumor lines tested (Table 1). Certain tumor cell lines, including those derived from the colon, lung, and head and neck lines, seemed to be marginally sensitive to AQ4N, but their IC50 values (12.3-103 μmol/L) were generally orders of magnitude higher than those observed with AQ4. There was no measurable activity of AQ4N against 13 of the 21 tumor cell lines tested under the normoxic conditions used in this assay (Table 1). These data support the evidence that the bioreduced metabolite AQ4 is significantly more cytotoxic than the prodrug AQ4N against human solid tumor lines from diverse tissue types, including those derived from the pancreas.

**Antitumor efficacy of AQ4N in multiple pancreatic xenograft models.** Based on the potent growth-inhibitory activity of AQ4 shown in the pancreatic tumor cell lines in vitro, we explored the antitumor activity of AQ4N in vivo using human Panc-1 or BxPC-3 pancreatic xenograft models. In each case, a range of AQ4N dose schedules was evaluated to determine the optimum dosage for efficacy as a single agent. Gemcitabine, a pyrimidine antimetabolite currently used to treat advanced and metastatic pancreatic cancers, was used as a comparison for AQ4N activity in these models.

In the Panc-1 model, the end point of the study was predefined to be when tumors reached 1,200 mm³ and treatment outcome was determined from TGD as described in Materials and Methods. As shown in Fig. 1A, AQ4N was observed to significantly inhibit the growth of Panc-1 tumors in vivo. AQ4N-dosed mice at 90 mg/kg q3d × 6 (given once every 3 days for a total of six times) or 120 mg/kg weekly × 8 resulted in a TGD of 20.2 days (70%; P = 0.02) and 27.7 days (96%; P = 0.02), respectively, compared with the vehicle control group. Furthermore, mice treated with AQ4N showed a significant increase in the median time to end point (49 days for AQ4N 90 mg/kg q3d × 6; 56.5 days for AQ4N 120 mg/kg weekly × 8) compared with the vehicle control-treated animals (28.8 days; Fig. 1A). In addition, both AQ4N treatment groups had significantly greater (P = 0.02) antitumor activity compared with the standard agent gemcitabine in this model. Mice treated with gemcitabine had a time to end point of 34.2 days, resulting in a nonsignificant TGD of 5.4 days (19%; Fig. 1A). Tumor volume measurements for each group over time following initiation of treatment are shown in Fig. 1B.

In general, AQ4N at the doses and schedules tested resulted in short-term body weight loss that was recovered following cessation of treatment (Fig. 1C). Treatment of mice with AQ4N at 90 mg/kg q3d × 6 was well tolerated as evident by a maximum body weight loss of only 4.3% observed on day 2. This was similar to gemcitabine treatment, which produced a maximum body weight loss of 5.3% on day 3. The AQ4N 120 mg/kg weekly × 8 schedule was tolerated for the initial six treatments as evident by minimal body weight loss; however, the last two treatments were less tolerated and resulted in 17.3% weight loss at day 52. Therefore, a shorter-term schedule of weekly AQ4N dosing was used in subsequent studies.
To extend our observations in other pancreatic tumor types and to explore the effects of AQ4N on metastasis, we then studied the human BxPC-3 pancreatic carcinoma model. Initially, we examined the effects of AQ4N or gemcitabine on preestablished (60-80 mm$^3$) BxPC-3 tumors grown s.c. using TGI as the readout. AQ4N activity against syngeneic tumors by physical or chemical methods, has been shown to enhance in vivo therapeutic outcome compared with AQ4N with a median survival of 40 days ($P$ < 0.001). Mice treated with AQ4N at 60 mg/kg q3d × 6 showed the highest TGI (58.8%) compared with the vehicle control group ($P$ < 0.001; Fig. 2A). In addition, weekly treatment using AQ4N at 120 mg/kg also showed significant TGI (42.4%) in a manner comparable with gemcitabine treatment (51%).

Having observed significant activity in two different s.c. models, we next investigated the effects of AQ4N in prolonging the survival of tumor-bearing mice in a more clinically relevant and highly aggressive orthotopic model of BxPC-3 pancreatic carcinoma. In this model, control mice that are surgically injected with tumor cells into the pancreas parenchyma succumb to tumor burden with a median survival time of 36 days (Fig. 2B). The same dose schedules of AQ4N (60 mg/kg q3d × 6 and 120 mg/kg q weekly × 3) that resulted in efficacy in the s.c. BxPC-3 model were also evaluated in this orthotopic model with the treatment being initiated on day 14 following tumor implantation. As shown in Fig. 2B, AQ4N treatment prolonged the survival of tumor-bearing mice in a statistically significant manner. Mice treated with AQ4N at 120 mg/kg q weekly × 3 showed a prolonged median survival of 44 days ($P$ = 0.05), whereas those treated with AQ4N at 60 mg/kg q3d × 6 had a median survival time of 41 days ($P$ = 0.03; Fig. 2B). Interestingly, gemcitabine treatment resulted in a similar therapeutic outcome compared with AQ4N with a median survival of 40 days ($P$ = 0.04) from this highly aggressive tumor (Fig. 2B).

**Effects of AQ4N treatment in reducing metastasis of orthotopic BxPC-3 tumors.** Orthotopic implantation of BxPC-3 tumor cells into the pancreas of mice results in the development of metastatic lesions in multiple organs, including the liver, lymph nodes, and spleen, as detected by intravital microscopy (39). To evaluate whether AQ4N treatment had an effect on liver metastasis in this model, we did histopathologic analyses on primary liver tissue sections ($n = 5$/group) harvested on day 36 after tumor challenge (Fig. 3). As expected, gross pathologic analysis of vehicle control mice showed large invasive primary tumors at the site of the pancreas (data not shown). In addition, histologic analyses of livers from four of five control mice showed the presence of large invasive tumors; an example is seen in Fig. 3A in which a metastatic lesion of ~50% of the size of the primary tumor is seen invading the liver. In contrast, liver metastases were observed in only two of five mice following AQ4N treatment (Fig. 3B). In addition to impeding the incidence of metastatic spread, AQ4N treatment (120 mg/kg) was also observed to significantly affect the size of the invading metastatic lesion (Fig. 3A and B). The fraction of liver tissues occupied by metastatic tumor cells in comparison with the percentage of total liver tissue indicated a pronounced reduction in the size and percentage of metastatic tumors following AQ4N treatment (Fig. 3B). Although a dose response was not evaluated, the antimeetastatic effects were qualitatively and quantitatively more pronounced in the 120 mg/kg AQ4N–treated group than in the 60 mg/kg AQ4N–treated group (Fig. 3A and B). Thus, in addition to having significant effects in delaying tumor growth progression and prolonging survival of tumor-bearing mice, AQ4N treatment also seems to have an effect in reducing liver metastasis emanating from orthotopically implanted BxPC-3 pancreatic tumors.

**Selective tumor targeting of the prodrug AQ4N in pancreatic xenografts in vivo.** AQ4N is designed to be a prodrug that is inert in most tissues until it is bioactivated to a potent cytotoxin under hypoxic conditions. Although tumor hypoxia, produced by physical or chemical methods, has been shown to enhance AQ4N activity against syngeneic tumors in vivo (31, 40), the...
selective tumor-targeting and pharmacokinetic properties of AQ4N and its metabolites in experimental human cancer models have not been studied extensively. Therefore, we evaluated the systemic and local tumor concentrations of the AQ4N prodrug and its bioreduced metabolites, AQ4M and AQ4, following treatment in BxPC-3 tumor-bearing mice using quantitative analytic procedures (HPLC-MS/MS).

As shown in Fig. 4, tumor and plasma pharmacokinetics of AQ4N, AQ4M, and AQ4 were evaluated at 2, 8, and 24 h following a single i.v. administration of AQ4N at 20, 60, 120, or 240 mg/kg. AQ4N was only detectable in plasma samples at 2 h following drug administration. Consistent with previous reports, AQ4N was observed to be rapidly eliminated from the systemic circulation, with only trace amounts

Fig. 3. Effects of AQ4N treatment on liver metastases following orthotopic BxPC-3 tumor implantation. A, livers were resected on day 36 after tumor challenge, paraffin embedded, and stained with H&E. Two representative H&E-stained liver sections from control-treated (top), 60 mg/kg AQ4N–treated (middle), and 120 mg/kg AQ4N–treated (bottom) groups. Magnification, ×100. B, AQ4N decreases the incidence and invasiveness of metastasis BxPC-3 lesions in the liver (n = 5/group). To compute metastasis index, five histologic sections from each liver were analyzed by microscopy and scored for the mean (±SE) percentage of area occupied by the invading BxPC-3 tumor lesion in comparison with the total liver tissue area analyzed. Evaluation of blinded samples was done by two independent operators. Statistical analysis was done using the nonparametic Mann-Whitney U test.
Fig. 4. Tumor and plasma pharmacokinetics of AQ4N, AQ4M, and AQ4 in BxPC-3 tumor-bearing mice. Following a single administration of 20, 60, 120, or 240 mg/kg AQ4N, primary BxPC-3 tumors or plasma samples were collected at 2, 8, and 24 h and subjected to HPLC-MS/MS for quantitative analysis. Points, mean plasma and tumor concentrations of AQ4N, AQ4M, and AQ4 plotted as a function of time after treatment (left) or versus treatment dose (right); bars, SD. A, plasma concentrations of AQ4N plotted versus AQ4N treatment dose or time. The bioreduced metabolites AQ4M and AQ4 were undetectable in the plasma at any of the treatment doses or time points investigated (data not shown). B, concentrations of AQ4N in the tumor and plotted versus treatment dose or time. C, concentrations of the intermediate AQ4M metabolite measured in the tumor and plotted as a function of AQ4N treatment dose or time. D, concentrations of the cytotoxic AQ4 metabolite measured in pancreatic tumors and plotted against the input treatment dose or time.
detectable in the plasma after 24 h at the highest dose (Fig. 4A; ref. 41). Importantly, the activated cytotoxic metabolite AQ4 was not detectable in the plasma at any dose or time point, and only trace amounts of the mono-N-oxide intermediate AQ4M were observed at 2 h for the 240 mg/kg dose sample (data not shown). These data indicate that AQ4N does not undergo systemic bioactivation and the prodrug is rapidly eliminated from the general circulation in vivo.

Consistent with its high tissue permeability, AQ4N was found at high levels in tumors only at the earliest time point (2 h) for all doses, showing rapid penetration of the prodrug into tumor tissues. Tumor levels of AQ4N were roughly linear with dose when measured at 2 h, with no evidence of saturation at the highest dose used (Fig. 4B). Concentrations of AQ4N detected in the tumor rapidly decreased over time, with little remaining at 24 h for all doses (Fig. 4B). Tumor accumulation of the mono-N-oxide AQ4M was approximately linear with increasing dose at 2 h following drug infusion (Fig. 4C). However, AQ4M was relatively short lived in tumors following treatment, as expected for an intermediate metabolite, and was present at minimal levels by 8 h for most doses (Fig. 4C). For the highest treatment dose of 240 mg/kg, AQ4M tumor clearance was slower as evident by the increased area under the plasma concentration versus time curve but reached substantially low levels by 24 h (Fig. 4C).

The activated cytotoxic metabolite AQ4 was found at high levels in all tumor samples at all time points, showing unambiguous localized activation of the prodrug in tumor tissues (Fig. 4D). Following treatment, AQ4 levels accumulated in the tumor in prodigious amounts (1.3-9.0 μg/g tumor tissue) and with rapid kinetics, as observed by 55% to 85% of near maximal levels after 2 h after infusion for all doses and 80% to 100% of conversion occurring by 8 h (Fig. 4D). The levels of AQ4 observed at 24 h are likely to be near maximal, as little AQ4N or AQ4M seemed available at this time point for further metabolic conversion (Fig. 4B and C). Previous studies have shown that AQ4 can be detected in tumor tissues for at least 2 weeks following a single 20 mg/kg dose of AQ4N, indicating the persistence of this highly stable DNA intercalator in vivo. In this study, quantitative detection using HPLC-MS/MS indicates that AQ4 selectively accumulates in human BxPC-3 tumors in a nearly linear dose-dependent fashion (Fig. 4D). These data provide clear demonstration that AQ4N undergoes rapid and selective conversion into the potent antineoplastic metabolite AQ4 in pancreatic tumors in vivo and supports the further development of hypoxia-activated prodrugs as tumor-targeting agents.

### Discussion

Pancreatic tumors display significant regions of hypoxia that are often resistant to cell killing by radiation and certain chemotherapeutics (6-10). Hypoxia-activated prodrugs, such as AQ4N, are designed to selectively target hypoxic tumor tissues while having minimal systemic toxicity. In this present study, we show for the first time that AQ4N undergoes dose-dependent and selective tumor activation in vivo, which results in significant inhibition of tumor growth and progression in several pancreatic xenograft models. In the aggressive BxPC-3 orthotopic model, treatment with AQ4N prolonged the median survival of tumor-bearing mice in a manner comparable with gemcitabine. Given that AQ4N may undergo metabolic activation only in hypoxic fractions, it is plausible that enhanced antitumor effects may be observed when AQ4N is combined with other agents that target oxygenated tumor regions, such as gemcitabine or radiation. In previous studies using syngeneic squamous cell carcinoma, fibrosarcoma, or mammary carcinoma models, AQ4N possessed marginal antitumor effects as a single agent but showed a >2-fold increase in activity when combined with radiation or chemotherapy (20, 31, 40, 42, 43).

In vitro, the bioreduced AQ4 metabolite was shown to inhibit the viability of multiple human pancreatic tumor lines with an apparent IC50 in the low micromolar range in contrast to the minimal activity of the AQ4N prodrug under normoxic conditions. The IC50 measured in our 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays may underestimate the true cytotoxicity of AQ4 because our studies only measured cell viability indirectly at 72 h following treatment. Using the more sensitive clonogenic assay, which may be more predictive of cell killing by DNA-damaging agent conditions (31, 44), previous studies have shown that AQ4 induces cytotoxicity with submicromolar IC50 activity in several human tumor lines under aerobic conditions (31, 44). Nevertheless, our studies extend previous observations that the AQ4N prodrug is relatively nontoxic or displays >100-fold less toxicity compared with the bioreduced AQ4 metabolite in a broad spectrum of human tumor cell lines in vitro.

Hypoxia has been shown to influence metastatic disease progression in several preclinical and human studies (1, 14, 15). Prolonged tumor hypoxia increases genomic instability, selects for metastatic variants, and alters the expression of genes involved in cell adhesion, migration, and tissue remodeling (1, 11-15). Given that AQ4N is selectively activated in hypoxic cells, we postulated that treatment may influence metastatic tumor development in the malignant orthotopic BxPC-3 model. Our observations indicate that AQ4N treatment reduces the incidence and growth of micrometastatic liver tumors in vivo. Based on the limited number of samples and time points analyzed, it is currently unknown whether the antitumor effects observed are a result from the cytolsys of a subset of metastatic tumor populations at the primary site or whether AQ4N may target the growth and invasiveness of disseminated tumor cells within hypoxic sites in the liver. These results are also consistent with recent reports showing reduced metastatic tumor dissemination in murine tumor models using other hypoxia-activated cytotoxins, including tirapazamine (45).

The pharmacokinetics of AQ4N and its metabolites in plasma and tumors seem consistent with its prodrug mode of action. Linear dose-dependent accumulation of the AQ4N and its bioreduced metabolites was readily observed in tumor tissues shortly following drug infusion. The kinetics of AQ4 and AQ4M appearance support the notion that AQ4N is rapidly metabolized to AQ4 in tumors through a relatively short-lived intermediate. Although the amount of tumor AQ4 increased in a linear fashion over the range of doses tested, the therapeutic effects related to dose dependency in our tumor models were less than obvious. Our studies indicate

---

3 A.S. Lalani et al., unpublished observation.
that AQ4 accumulates in BxPC-3 tumors at concentrations (3.59–20 μmol/L) that are 2- to 12.5-fold greater than the predicted IC_{50} from in vitro analysis. As tumor hypoxia can be heterogeneous, it is difficult to accurately assess the fraction or subset of BxPC-3 tumors that trigger AQ4N bioactivation and oncolysis. Interestingly, AQ4 was recently shown to be tumor selective and colocalize with the Glut-1 hypoxic marker in human tumor biopsies following treatment in a phase I pharmacodynamic study (46).

Once reduced, AQ4 is unlikely to diffuse far from its producer cell given its potent DNA-binding affinity (34). Importantly, the rapid systemic clearance of AQ4N and the absence of the metabolites in the plasma indicate that bioactivation of the prodrug does not occur in the circulation. These mass spectral data are consistent with other clinical and preclinical pharmacokinetic studies showing that systemic levels of AQ4 and AQ4M represent <2% of the input prodrug (41, 47–49). As a consequence, AQ4N would not be expected to have serious systemic toxicities in vivo given its primary tumor localization and limited bystander effects. Although we did not do an exhaustive analysis of other normal tissues in our preclinical models, biodistribution studies show predominant drug localization in BxPC-3 tumors, large intestine, and spleen, which persisted for over 2 weeks following a single administration of 20 mg/kg [14C-methyl]AQ4N (data not shown). Indeed, clinical exposure of AQ4N with doses as high as 750 mg/m² has been well tolerated with minimal systemic toxicities, including skin and urine discoloration, and fatigue (47–49). These data support the rationale for the development of bioreductive prodrugs, such as AQ4N, as a potentially safe therapy for hypoxic tumors, such as pancreatic adenocarcinomas. Further preclinical and clinical studies combining AQ4N with radiation and other chemotherapies are currently under way and may yield enhanced therapeutic effects by targeting both the oxygenated and hypoxic regions of this aggressive neoplasm.

References


Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

Alshad S. Lalani, Susan E. Alters, Alvin Wong, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/13/7/2216

Cited articles
This article cites 47 articles, 7 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/13/7/2216.full.html#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
/content/13/7/2216.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.